Article Text

Download PDFPDF
Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia
  1. S. N. Tabrizi*,,
  2. I. H. Frazer and
  3. S. M. Garland*,
  1. * Department of Microbiology and Infectious Diseases, University of Melbourne, The Royal Women's Hospital, Carlton, Victoria, Australia
  2. Department of Obstetrics and Gynaecology, University of Melbourne, The Royal Women's Hospital, Carlton, Victoria, Australia
  3. Department of Centre for Immunology and Cancer Research, The University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia
  1. Address correspondence and reprint requests to: Sepher N. Tabrizi, The Royal Women's Hospital, 132 Grattan St., Carlton, VIC, 3053, Australia. Email: sepehr.tabrizi{at}


This study evaluated the detection of human papillomavirus (HPV) 16 antibody in HPV 16–associated cervical intraepithelial neoplasia (CIN) in Australian women. Seroreactivity to HPV 16 L1 virus–like particles was assessed in patients with CIN 2 (n = 169) and CIN 3 (n = 229) lesions previously tested for the presence of HPV DNA. Seropositivity was significantly commoner in women with HPV 16 DNA–positive lesions (98/184) than in women with no HPV DNA in the lesion (15/47) or with HPV of types other than 16 in the lesion (43/167) (P = 0.0004). In addition, seropositivity was observed in 33% (55/169) of women with CIN 2 and 46% (106/229) of women with CIN 3, in keeping with the lower fraction of CIN 2 (57/169) than CIN 3 (127/229) biopsies positive for HPV 16 DNA. HPV 16 seropositivity is most common in women with HPV 16–associated CIN, but many patients with HPV-associated CIN 3 are seronegative, and HPV 16 seropositivity is common in women with CIN associated with other HPV types. Overall, HPV 16 serology is a poor predictor of presence of HPV 16–associated CIN 3 in patient population studied.

  • cervical cancer
  • CIN
  • HPV
  • serology
  • VLP

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.